Allarity Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Allarity Therapeutics cut operating losses, resolved SEC matters, and advanced its PARP/tankyrase inhibitor stenoparib with Fast Track status and new trials while maintaining $14.7M cash at year-end.
NASDAQ
Allarity Therapeutics streamlines operations to focus on stenoparib, a novel cancer therapeutic, while reporting financial results for the year ended December 31, 2024.
NASDAQ
10-K/A: Allarity Therapeutics Files Amended 10-K to Include Missing Information and New Certifications
Allarity Therapeutics has filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive compensation, and other corporate governance matters.
NASDAQ
Allarity Therapeutics shifts its focus to stenoparib development in ovarian cancer, deprioritizing other assets and streamlining operations.